Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599260 | 1.00 | ALDH1A1 (0.47) | ALDH1A1DRD3KMT2AMAPTCASP3 | |
| SCHEMBL14318320 | 1.00 | ALDH1A1 (0.47) | ALDH1A1DRD3KMT2AMAPTCASP3 | |
| SCHEMBL9340887 | 0.88 | ALDH1A1 (0.53) | ALDH1A1DRD3KMT2ACASP3CA12 | |
| SCHEMBL4580570 | 0.86 | ALDH1A1 (0.45) | ALDH1A1DRD3KMT2AMAPTCASP3 | |
| SCHEMBL14928649 | 0.83 | ALDH1A1 (0.49) | ALDH1A1DRD3KMT2ACASP3CA12 | |
| SCHEMBL14393320 | 0.83 | ALDH1A1 (0.49) | ALDH1A1DRD3KMT2ACASP3CA12 | |
| SCHEMBL14928796 | 0.83 | ALDH1A1 (0.49) | ALDH1A1DRD3KMT2ACASP3CA12 | |
| SCHEMBL7296253 | 0.83 | ALDH1A1 (0.49) | ALDH1A1DRD3KMT2ACASP3CA12 | |
| SCHEMBL4579022 | 0.83 | ALDH1A1 (0.43) | ALDH1A1DRD3KMT2AMAPTMAOB | |
| SCHEMBL11024056 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTCASP3GLSMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003209-B | Macrocyclic compounds as TRK kinase inhibitors | 阵列生物制药公司 | 2022-01-25 | — | — | CN | disclosed |
| US-20200291026-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2020-09-17 | — | — | US | disclosed |
| US-10647730-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3521291-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190031684-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-01-31 | — | — | US | disclosed |
| EP-3205654-B1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-9902741-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9840519-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170283435-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9750744-B2 | Macrocyclic compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-5587469-A | USEFUL AS ?ANTISENSE AGENTS? THAT ARE CAPABLE OF SPECIFIC HYBRIDIZATION WITH A NUCLEOTIDE SEQUENCE OF AN RNA | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0742790-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0731807-A1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5543507-A | BONDING STRANDS OR ONE STRAND AT DIFFERENT SITES; RNA MIMICS FIXED IN SPATIAL CONFORMATION; NUCLEASE RESISTANT MIMICS OF BINDING RECEPTORS FOR NUCLEIC ACID-BINDING PROTEINS; 5-LIPOXYGENASE INHIBITORS; DIAGNOSIS; ANALYZING | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0635023-A4 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES. | ISIS PHARMACEUTICALS INC (US) | 1996-03-20 | — | — | EP | disclosed |
| US-5459255-A | For incorporation into oligonucleotides, cleaving RNA site specifically | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995014707-A1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0635023-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291026-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | ALDH1A1 4546/4885DRD3 1073/4885KMT2A 809/4885 |
| US-20190031684-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | ALDH1A1 4492/4885DRD3 2377/4885KMT2A 844/4885 |
| US-20170283435-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | ALDH1A1 4546/4885DRD3 1073/4885KMT2A 809/4885 |
| US-10647730-B2 | Macrocyclic compounds as TRK kinase inhibitors | MAP3K20, MAP3K1, MAP3K3 | ALDH1A1 4492/4885DRD3 2377/4885KMT2A 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.